Multi-component, multi-target actions of Wuzi Yanzong Pill in male infertility: An evidence map linking clinical signals to mechanistic networks.

A PRISMA-screened evidence map finds mechanistic plausibility but only 8 clinical trials — most evidence is animal data

Journal: Journal of Ethnopharmacology | Published: 2026-04-16 | Type: Review, Evidence Map | PMID: 42000002 Authors: Ren Xiaoli, Chen Ken, Li Shu, Wang Tongsheng, Li Jingya et al. (Department of Pharmacology, Anhui University of Chinese Medicine, Hefei, China) Funding/COI: Funding not listed. Authors declare no competing financial interests.

Summary

Wuzi Yanzong Pill (WZYZP) is a classical Traditional Chinese Medicine formula used for oligoasthenozoospermia (OAT). This review screened 1,140 records and retained 135 publications to map the evidence linking clinical outcomes to proposed mechanisms. The honest summary: 56 preclinical (mostly animal) studies point toward effects on oxidative stress, mitochondrial function, and spermatogenesis, while only 8 clinical trials exist — and those are too heterogeneous to draw firm conclusions from.

Claims

• 135 publications retained from 1,140 screened; 64 were WZYZP intervention studies, of which 56 were preclinical and only 8 were clinical
• Clinical studies reported improvements in semen concentration, motility, morphology, and reproductive hormones, but were heterogeneous across formulation sources, diagnostic criteria, comparators, and endpoints
• Preclinical data converged on several pathways: redox and lipid-peroxidation control, mitochondrial bioenergetics, apoptosis modulation (Bcl-2/Bax-caspase axis), inflammatory signaling, blood-testis barrier integrity, and HPG-axis/steroidogenesis support
• 71 mechanistic publications included in silico analyses (network pharmacology, molecular docking/dynamics) and single-constituent studies
• No meta-analysis was performed due to clinical heterogeneity
• Authors explicitly call for formula standardization, pharmacokinetic-informed dosing, biomarker-guided target validation, and registered trials with pregnancy/live-birth outcomes

Study Quality

This is an evidence map, not a meta-analysis — the authors are transparent about that distinction. The PRISMA-informed screening workflow is appropriate for the stated aim of identifying research gaps rather than pooling effect sizes. Searching six databases including CNKI (Chinese) through December 2025 is a genuine strength, since much TCM research is published only in Chinese literature.

The fundamental problem is the evidence base itself: 56 preclinical studies versus 8 clinical trials is a deeply lopsided ratio. The clinical trials are described as heterogeneous in formulation, diagnosis, comparators, and endpoints — meaning they cannot be meaningfully synthesized. No pregnancy or live-birth data exists. The in silico studies (network pharmacology, molecular docking) are hypothesis-generating at best and are often used in TCM literature to manufacture a veneer of mechanistic credibility without functional validation.

Red Flags

• Only 8 clinical trials for a formula described as "long used" — a striking gap between traditional use claims and actual human evidence
• Formulation is not standardized: different studies use different sourcing and preparations, making cross-study comparison impossible
• No pharmacokinetic data to establish what constituent concentrations actually reach target tissues
• Heavy reliance on network pharmacology and molecular docking, which are computational exercises that do not confirm biological activity
• No pregnancy or live-birth outcomes reported in any clinical study — the only outcomes that matter for an infertility treatment
• All authors are from a single TCM university; no independent external validation
• Funding source not disclosed

Strengths

• PRISMA-informed methodology and explicit scope (evidence mapping, not meta-analysis) is honest about what the data can support
• Inclusion of CNKI captures Chinese-language literature often missed by Western reviews
• Authors clearly identify the translational gaps rather than overselling the evidence
• Mechanistic convergence across multiple preclinical studies on oxidative stress and mitochondrial pathways provides coherent (if unproven) hypotheses for future study

Verdict

This paper is a well-executed map of a weak evidence base. The authors deserve credit for not overselling: they explicitly state findings "should be interpreted with caution" and call for adequately powered registered trials. But the underlying literature is thin — 8 heterogeneous clinical trials with no live-birth data is not a foundation for clinical confidence, regardless of how many animal studies or molecular docking models surround it. For anyone trying to understand the state of WZYZP evidence, this is the most comprehensive synthesis available. For anyone hoping the evidence is good enough to act on, it isn't.